Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

office blood pressure measurements (OBPM) with standard equipment (i.e. a mercury sphygmomanometer or aneroid device) during each study visit.

Both doses of naproxcinod were shown to be safe and well tolerated, with 46.7% and 40.8% of patients experiencing at least one adverse event at 750 mg and 375 mg bid, respectively. In the naproxen and placebo bid groups, 56.4% and 38.7% of patients experienced at least one adverse event, respectively. In terms of gastro-intestinal adverse events, the naproxcinod 750 mg and 375 mg bid treatment groups reported event rates of 17.0% and 12.9%, respectively and the naproxen and placebo bid groups reported event rates of 23.6% and 12.2%, respectively. The number of serious adverse events was low and evenly spread among the treatment groups.

"I am very pleased to be presenting these phase 3 data for naproxcinod at the ACR meeting, which is considered to be one of the leading events for the scientific and medical community in rheumatology," declared Thomas J. Schnitzer, MD, PhD, Professor of Medicine at Northwestern University Feinberg School of Medicine, Principal Investigator on the 301 study. "Naproxcinod exerts its therapeutic effect through the well-described inhibition of the cyclo-oxygenase system and a sustained donation of nitric oxide. In this clinical setting, nitric oxide may exert a protective effect in the gastro-intestinal tract and play a homeostatic role in blood pressure control. These phase 3 results suggest that naproxcinod may offer a promising clinical and pharmacological profile for the treatment of the signs and symptoms of osteoarthritis. These findings will need to be confirmed by the ongoing 302 and 303 studies."

Details of the 301 study design and patient characteristics

A total of 918 patients were randomized at 120 clinical sites in the United States to receive either naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 500 mg bid or placebo bid for 13 weeks. Eligible patien
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ATLANTA , Jan. 23, 2015 More than a ... a quarter of those with private insurance, filled a prescription ... to a report in this week,s Morbidity and Mortality Weekly ... health care providers to treat moderate to severe pain.  They ...
(Date:1/23/2015)...  Now available for sale, The Armor1 Ankle Roll Guard is ... sprains by cushioning the ankle from an inversion or ... outside of any shoe type and allows the user ... protection against sprains. With customers in physical therapy, podiatry, ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... and NUREMBERG, Germany, April 13, 2012 ... of mobile C-arms presents its award-winning product portfolio ... Together with Xograph ( http://www.xograph.com ), its UK ... vascular specialists, interventional radiologists and cardiologists to provide ...
... ("Unilife" or "Company") (NASDAQ: UNIS ;  ASX: UNS) announced ... fiscal 2012 third quarter ended March 31, 2012 after market trading ... scheduled a conference call for 4:30 p.m. U.S. EDT on Thursday, ... AM AEST) , to review the Company,s financial results, market ...
Cached Medicine Technology:CX 2012: Elevating the Boundaries of Interventional Imaging with Mobile C-arms 2Unilife Corporation to Announce Financial Results for Fiscal 2012 Third Quarter on Thursday, April 26, 2012 2Unilife Corporation to Announce Financial Results for Fiscal 2012 Third Quarter on Thursday, April 26, 2012 3
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy ... its highest annual revenues in the past three years. Today, ... wedding dresses. , According to the sales manager of the ... for them in 2015. This point can be reflected on ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... the consumer into a false sense of complete protection, ... commission has got its act together on this issue, ... lotions and its allied products. ,The labels that ... labeling a total protection message are: “sun blocker" or ...
... the four-and-a-half-year-old marathon kid of Orissa, declared that his health ... a medical check up after he ran an astounding 65km ... government-run Capital Hospital at Bhubaneswar for a medical check up ... probing allegations that coach Biranchi Das was exploiting the boy ...
... undergo the monthly ordeal of PMS, those who have a ... their counterparts //, reveals a new study. ,Time ... blamed for mood swings, lethargy and pain associated with premenstrual ... husbands who lack compassion for their wives can make matters ...
... Health officials of the NHS Grampian said that people were ... The NHS health board said so defending their decision to ... ,A spokeswoman for NHS Grampian said a doctor ... suitable for a patient to stay outwith the city's Royal ...
... was found on Sunday, has mystified Boston police who are ... to find if anyone filled canisters during the last weekend. ... Park where the body was found. Police say the 19-year-old ... body was moved to a wooded area in Franklin Park ...
... have developed a new vitamin-A drug, which may be ... younger patients, but also added that more research is ... a leading charity committed to fighting breast cancer through ... studying 1,700 women between 12 and 16 years, reported ...
Cached Medicine News:Health News:Marathon Kid Budhia’s Health Not Compromise 2Health News:Supportive Husbands Can Help Ease PMS 2
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone...
... The procedure follows the basic principle ... is competition between an unlabeled antigen and ... binding sites of a specific antiserum . ... biotin-labelled estrone) bound to the antibody is ...
... (5-Androstene-3-0L-17-one,Androstenolone, Dehydroisoandrosterone,Transdehydroandrosterone, DHEA) is a ... mostly in its,sulfate form (DHEA-S). ... based on the competition principle ... amount of DHEA-S present in ...
... Angiotensin Converting Enzyme (ACE), also known ... (EC 3.4.15.1) with a molecular weight of ... glycoprotein shows a single polypeptide chain, a ... is present in many different cell types ...
Medicine Products: